• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Expanded Access

Every approved medication has been tested to show that it is safe and effective. This testing can take a decade or more, which for many people living with a serious disease is too long to wait.

Regulators such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have taken steps to speed up parts of this process so that important drugs reach people sooner. One of these steps is expanded access, also called compassionate use. Expanded access gives people with a serious or life-threatening illness early access to a drug that is still being tested and has not yet been approved.

On this page

When expanded access is allowed  │  Expanded access and ALS/MND  │  Risks  │  Learn more

When expanded access is allowed

Drugs in expanded access are not yet proven to be safe and effective. For this reason, regulators generally prefer that people take part in a clinical trial first. They also take steps to make sure people are not exposed to undue risk.

In the United States, the FDA may allow expanded access when all of the following apply:

  • The person has a serious or immediately life-threatening illness, and no comparable or satisfactory treatment is available to them.
  • The person cannot enroll in a clinical trial, either because no trial is available or because they are not eligible for any trial.
  • The potential benefit of the drug justifies the potential risks.
  • Giving the drug will not interfere with the clinical trials that are needed to approve it.

In the European Union, each member state sets its own rules and runs its own compassionate use programs. The EMA gives recommendations on how a medicine should be used in these programs, but these recommendations do not create a legal framework. Rules in other countries differ. Ask your doctor or your national regulatory agency what is available where you live.

Forms of expanded access

Expanded access takes several forms:

  • A program for a large group of people, to bridge the gap between the end of a clinical trial and marketing approval.
  • A program for a smaller group of people who need a drug that is not being actively developed for clinical use.
  • Permission for a doctor to give an individual person an investigational drug in an emergency.

Expanded access for people living with ALS/MND

ALS/MND is a serious, life-threatening disease, and current treatment options are limited. Some experimental ALS/MND drugs may therefore qualify for expanded access. Whether you are eligible depends on the drug, your situation, and the country where you live. Talk with your ALS/MND doctor, who can tell you whether an expanded access program exists for a drug you are interested in.

Risks of expanded access

Regulators support expanded access, but they prefer that people take part in clinical trials. Clinical research offers more protection if a treatment is unsafe or ineffective, and clinical trials are the best way to prove a medication’s safety and effectiveness.

Remember that drugs offered through expanded access have not been approved for use. Researchers have not yet proven that they are safe and effective, and they may cause unexpected side effects. Discuss the risks with your doctor before making a decision.

Learn more

Expanded Access
US Food and Drug Administration

Compassionate use
European Medicines Agency

Open Label Extension
Continued access to a study treatment after a trial ends.

Recommendations for Trial Sponsors

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Marcelo Farinelli, Brazil

    Marcelo Farinelli, Brazil

  • Anna Barrow, UK

    Anna Barrow, UK

  • Sébastien Batiot, France

    Sébastien Batiot, France

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Eddy Lefrancois, Canada

    Eddy Lefrancois, Canada

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Hanne Stenmose, Denmark

    Hanne Stenmose, Denmark

  • Jose Rivero Muñoz, Mexico

    Jose Rivero Muñoz, Mexico

  • Liam Dwyer, England

    Liam Dwyer, England

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Rosie Riley, USA

    Rosie Riley, USA

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • David Watson, Scotland

    David Watson, Scotland

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Ailsa Malcolm-Hutton, UK

    Ailsa Malcolm-Hutton, UK

  • Timmy, Belgium

    Timmy, Belgium

  • Animesh Kumar, India

    Animesh Kumar, India

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Inta Grubb, Australia

    Inta Grubb, Australia

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Bayley, Australia

    Bayley, Australia

  • Cliff Marshman, USA

    Cliff Marshman, USA
    CliffMarshman

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Shera Mukherjee, India

    Shera Mukherjee, India

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Dan Doctoroff, USA

    Dan Doctoroff, USA

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Carlos Alberto Báez Murillo, Colombia

    Carlos Alberto Báez Murillo, Colombia

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Laurie Petit-Jean, France

    Laurie Petit-Jean, France

  • Barry de Reuver, Netherlands

    Barry de Reuver, Netherlands

  • Feng Gin Sun, China

    Feng Gin Sun, China

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Lombana, Spain

    Lombana, Spain

  • Purningam Jacob, India

    Purningam Jacob, India

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • Mike Small, UK

    Mike Small, UK

  • Claudia Cominetti, Italy

    Claudia Cominetti, Italy

  • Daniel Hare, USA

    Daniel Hare, USA

  • Alejandro Aquino, Argentina

    Alejandro Aquino, Argentina

  • Mary Thomas, Australia

    Mary Thomas, Australia

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login